Home
»
Press Room
»
Bioprocess Automation Market To Reach $22.41Bn By 2033

Bioprocess Automation Market To Reach $22.41 Billion By 2033

October 2025 | Report Format: Electronic (PDF)

Bioprocess Automation Market Growth & Trends

The global bioprocess automation market size is projected to reach USD 22.41 billion by 2033, growing at a CAGR of 12.67% during the forecast period, according to a new report by Grand View Research, Inc. The market is witnessing strong growth, fueled by rising demand for biologics, cell and gene therapies, regenerative medicine, and advanced vaccine manufacturing. As global biopharmaceutical R&D intensifies, manufacturers are using automated platforms more frequently to improve process efficiency, guarantee scalability, and maintain compliance with strict regulatory standards across a variety of applications.

Advanced bioprocess solutions are being adopted more quickly owing to strategic partnerships between biopharmaceutical companies, academic research centers, automation technology providers, and contract development and manufacturing organizations (CDMOs). Complex biologics can be scaled up faster and reliably when high-throughput automation, real-time monitoring, and predictive analytics are combined to optimize workflows and lower operational risks.

The market for bioprocess automation is expected to be crucial in facilitating manufacturing efficiency, regulatory compliance, and technological innovation throughout the global drug development and production pipeline as the biopharmaceutical industry increasingly depends on cell and gene therapies, personalized medicine, and next-generation biologics.

key Request a free sample copy or view report summary: Bioprocess Automation Market Report

Bioprocess Automation Market Report Highlights

By product & service, process automation hardware was the largest segment in the market in 2024, capturing a market share of 30.36%. This dominance can be attributed to the widespread adoption of monitoring devices, controllers, and sensors that facilitate accuracy in controlling bioprocess parameters. Hardware is fundamental in maintaining reliability and availability, reducing human error, and ensuring scalability of biopharmaceutical production. Advances in smart instruments and the integration of IoT-enabled platforms further reinforce this segment's leadership.
By process stage, the upstream segment led the market in 2024, capturing the largest market share of 34.91%. The growing demand for optimized bioreactors, cell culture systems, and media preparation technologies has driven the implementation of automation solutions in upstream processes. The Upstream segment, which focuses on improving cell productivity, reducing contamination opportunities, and fueling high-yield biologic manufacturing, continues to support its prominence in the market.
By end use, pharmaceutical and biotech manufacturers held the largest share of the market in 2024, accounting for 36.24%. Their demand for efficient, reproducible, and compliant bioprocessing systems is vital to the establishment of large-scale operations for biologics, vaccines, and advanced therapies. Furthermore, investments in manufacturing facilities and increased production capacity support these manufacturers in maintaining their leadership in the bioprocess automation industry.